Study identifier:4522IL/0101
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
A 24-week, randomised, open-label, parallel-group, multi-centre study which compares the efficacy and safety of rosuvastatin 10, 20 and 40 mg with atorvastatin 10, 20 40 and 80 mg when force titrated in the treatment of patients with primary hypercholesterolemia and either a history of coronary heart disease (CHD) or clinical evidence of atherosclerosis or a CHD risk equivalent (10 year risk score >20%).
hypercholesterolaemia
Phase 1
-
-
-
-
Interventional
-
Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -
-
AstraZeneca
-
No locations available
Arms | Assigned Interventions |
---|